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Abstract
Background: Genome wide association studies (GWAS) have proven useful as a method for identifying genetic variations
associated with diseases. In this study, we analyzed GWAS data for 61 diseases and phenotypes to elucidate common
associations based on single nucleotide polymorphisms (SNP). The study was an expansion on a previous study on
identifying disease associations via data from a single GWAS on seven diseases.
Methodology/Principal Findings: Adjustments to the originally reported study included expansion of the SNP dataset
using Linkage Disequilibrium (LD) and refinement of the four levels of analysis to encompass SNP, SNP block, gene, and
pathway level comparisons. A pair-wise comparison between diseases and phenotypes was performed at each level and the
Jaccard similarity index was used to measure the degree of association between two diseases/phenotypes. Disease
relatedness networks (DRNs) were used to visualize our results. We saw predominant relatedness between Multiple
Sclerosis, type 1 diabetes, and rheumatoid arthritis for the first three levels of analysis. Expected relatedness was also seen
between lipid- and blood-related traits.
Conclusions/Significance: The predominant associations between Multiple Sclerosis, type 1 diabetes, and rheumatoid
arthritis can be validated by clinical studies. The diseases have been proposed to share a systemic inflammation phenotype
that can result in progression of additional diseases in patients with one of these three diseases. We also noticed
unexpected relationships between metabolic and neurological diseases at the pathway comparison level. The less
significant relationships found between diseases require a more detailed literature review to determine validity of the
predictions. The results from this study serve as a first step towards a better understanding of seemingly unrelated diseases
and phenotypes with similar symptoms or modes of treatment.
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Introduction
Genome-wide association studies (GWAS) have become a
popular method for surveying genetic variations, such as single
nucleotide polymorphisms (SNPs) and classifying heritable risk
factors associated with a particular disease [1,2]. In an effort to
better understand the genetic basis of complex diseases, GWAS
have been made technically feasible and affordable due to the
completion of the Human Genome project [3,4], identification of
SNPs throughout the human genome by the International
Haplotype Map project (HapMap) [5,6], and the availability of
dense genotyping chips enabling simultaneous and cost effective
typing of millions of SNP loci [7]. GWAS have been carried out
for several commonly known diseases including inflammatory
bowel disease, type I and type II diabetes, asthma, breast cancer,
coronary artery disease, and prostate cancer [8]. Results from such
studies have demonstrated the potential for GWAS to detect a
range of genetic variability, including copy number and repeat
variants [7]. GWAS may also aid in improving understanding of
the effects of genetic variation on genes and pathways. However,
the ultimate objectives of such studies are to present a full
description of the susceptibility framework of major biomedical
traits and translate such findings towards the diagnosis and
treatment of diseases [8].
In this study, we performed a large-scale comparison of 61
diseases and phenotypes by expanding on studies conducted by the
Wellcome Trust Case Control Consortium (WTCCC) [9] and
Huang et al. [10]. The WTCCC study examined 2000 diagnosed
individuals and about 3000 controls for coronary artery disease
(CAD), hypertension (HYP), type II diabetes (T2D), rheumatoid
arthritis (RA), Crohn’s disease (CD), type I diabetes (T1D), and
bipolar disorder (BD). All participants in the study were from the
British population. Using SNPs from the WTCCC study, Huang
et al. [10] performed analyses at four levels: nucleotide, gene,
protein, and phenotype. The goals of the study included:
identification of overlap across SNPs associated with the seven
diseases, analysis of genetic commonalities, protein-protein
interaction network construction, and exploration of phenotypic
similarities between diseases. The group found strong associations
across all four levels of analysis for the autoimmune group (CD,
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level within the metabolic/cardiovascular group (CAD, HYP, and
T2D). These results reasserted some expectations based on clinical
literature in the case of the autoimmune group, and suggested
inappropriate disease grouping in the case of the metabolic/
cardiovascular group [10].
The purpose of this study was to predict the genetic basis of any
associations within an expanded set of human diseases and
phenotypes and develop networks based on disease/phenotype
relatedness. Data about genetic commonality may help in
discovering hidden relationships that do not initially appear
phenotypically but may prove useful in diagnostic or treatment
practices. A large-scale comparison study such as this has the
potential to uncover relationships between diseases and pheno-
types that are often ignored by single disease SNP data analysis.
Methods
Changes made to the Huang et al. protocol
Previously, Huang et al. [10] analyzed GWAS data for seven
diseases to uncover disease relatedness. We expanded the study
using the GWAS database curated by Johnson and O’Donnell
[11] and focused on 61 diseases and potential disease-associated
phenotypes. We characterized disease and phenotype relatedness
at four levels: nucleotide level, SNP block level, gene level, and
pathway level. Huang et al. [10] clustered SNPs on the same
chromosome based on a 1MB distance threshold; however, this
1MB cutoff was arbitrary and might not reflect the actual linkage
of neighboring SNPs on the chromosomes. Thus, we improved
this procedure by grouping SNPs based on linkage disequilibrium
(LD). Since LD along the chromosome varies among different
human populations, we used LD data for more than the single
British population used in the original GWAS. However, simply
cataloging LD data from multiple GWAS proved difficult as the
GWAS for the 61 diseases and phenotypes were done by various
research labs on various human populations. We therefore used a
single set of SNPs from dataset release #24 (2009-02_rel24) of the
HapMap database and the estimated LD data by the HapMap
project for five populations as a surrogate for the LD in the
original GWAS population [5,6]. The five populations were Han
Chinese (CHB), Japanese (JPT), a combined CHB and JPT
population (CHB+JPT), Yoruba (YRI), and U.S. residents with
northern and western European ancestry (CEU). We note that as
the LD estimates for the five populations might not be an accurate
reflection of the LD in the original GWAS population, this
procedure may have biased our results away from those found by
Huang et al. [10].
SNP Comparison
The initial list of SNPs was expanded using LD. We performed
a comprehensive search for all SNPs in strong to moderate LD
with the initial SNP set to include what might be causal SNPs
missing from the available GWAS data. For this search we used
the bulk LD data files produced by the HapMap project [5,6]. The
files were processed to extract SNPs having an r
2 value greater
than or equal to 0.5 with the SNPs in the initial set. Similarity
between the original and expanded datasets was assessed using the
Spearman correlation method. Perl [12] scripts were implemented
to count the number of similar SNPs between pairs of the 61
diseases and phenotypes in order to explore relatedness. Given
that there are 61 diseases/phenotypes and five populations, there
were a total of 9150 pairwise comparisons. The Jaccard index was
then calculated for each pair by computing the ratio of the number
of common SNPs to the total number of unique SNPs.
Block Comparison
SNPs were clustered into blocks based on LD as well. Huang
et al. suggested SNP clustering was rational given expression
patterns for proximal genomic regions tend to be similar and make
up parts of a combined response [10]. Therefore, identification of
significant patterns across diseases would be possible by analyzing
blocks of SNPs rather than individual variations [10]. A block
clustering algorithm was used to analyze the LD values between all
adjacent pairs of SNPs within the HapMap LD data files. Two
SNPs with an LD above the set r
2 threshold were clustered into the
same block, while SNPs with an LD below the threshold were
listed as separate blocks. Using a threshold of r
2$0.5 resulted in
approximately 50% of the blocks containing a single SNP, which
was not conducive to a proper comparison analysis. The threshold
was reduced to r
2$0.1, for which approximately 20% of the blocks
contained a single SNP.
To get a quantitative measure of commonalities between two
diseases, we compared the sets of SNP blocks belonging to each
disease. We implemented a script in the R programming language
[13] to count the number of common blocks across all diseases by
considering equal and overlapping blocks. Blocks meeting the
criteria were counted as being similar and used in the calculation
of the Jaccard index.
Gene Comparison
The block data was cross referenced against a list of human
gene names and chromosome positions derived from the Ensembl
Genome Browser [14]. Blocks that did not match a region
between gene start and end positions listed in the Ensembl dataset,
and did not have a distance of at most 2 kilobases from the start or
end positions of a gene, were excluded from the gene comparison
analysis. Some blocks did not match Ensembl gene information
and therefore no genes were available to compare. Disease and
phenotype pairs for which no gene associations could be made due
to lack of genes were assigned Jaccard indexes of zero to maintain
the number of compared diseases. Atrial Fibrillation/Atrial Flutter
(AF) in all populations and Progressive Supranuclear Palsy (PSP) in
the YRI population met this criterion.
Pathway Comparison
The Ensembl dataset was cross referenced against data from the
KEGG Pathway Database [15–17] to generate a directory of text
files containing KEGG pathway IDs associated with specific gene
IDs. Pathway ID lists were generated for each disease by
comparing the list of Ensembl gene names against the KEGG
gene name-specific pathway ID lists. Data were once again lost at
this level of analysis because the KEGG dataset does not list all the
genes found in the Ensembl dataset. Table S1 lists diseases with
index values of zero for comparisons in the final analysis level. As
with the gene level, Jaccard indexes were set to zero for these
diseases/phenotypes in order to maintain the number of diseases
included in the comparison analysis.
Principal Components Analysis
Principal components analysis (PCA) is generally used as an
exploratory tool to find hidden trends within high dimensional
data. The reduction in the dimensionality of the data is a
consequence of covariance analysis between variables or factors.
In this case, each level of analysis was considered a single factor
and significant relationships were extracted. These relationships
were clustered using a partitioning around medoids (PAM)
algorithm, which is a more robust version of the k-means method.
The number of clusters selected was three in order to divide the
GWAS-Based Disease/Phenotype Association
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associations’’, and ‘‘no associations’’.
The first step of analysis involved computing the principal
components from the variance covariance matrix. Next, a
regression model was fit where the independent variable was the
centered data and the dependent variables were the principal
components. The resulting regression coefficients were then
clustered using PAM. Additional details for this method are as
described by Beckman et al. [18].
Disease Relatedness Networks
Distribution curves were generated for each population at each
level of analysis (Figure S1). The curves represented counts for all
of the calculated Jaccard indexes. DRNs were generated with
Jaccard similarity index values using Cytoscape 2.8.1 [19]. For the
DRNs, edges connecting disease nodes represented the weighted
relatedness of the disease/phenotype pairs for each population and
level of analysis. The divisions for line color were set as the
quartiles for the range of indexes for the specified level. Line
thickness was also scaled from thin to thick relative to increasing
Jaccard index values.
Results
Expansion of SNP dataset
The GWAS data used for this study was derived from several
different SNP genotyping platforms. Each platform yielded
genotypes for only a subset of the approximate 10 to 30 million
SNPs in the human genome, and these tag SNPs were selected to
be representative of chromosomal regions in strong LD. However,
the tag SNP selection process is imperfect, and neighboring
disease-causing SNPs can thus be missing from GWAS results
[20]. For our analysis we attempted to restore these potentially
causal SNPs to an expanded dataset by finding SNPs in strong LD
with those present in the original Huang et al. GWAS dataset.
The 61 diseases/phenotypes explored in this study are listed in
Table 1. Phenotypes were considered in our analysis because we
hoped to find hidden genetic associations between phenotypes and
Table 1. List of phenotypes and diseases considered for this study and corresponding abbreviations. The list was taken from
Huang’s collected dataset.
Abbrev-iation Disease/Phenotype Abbrev-iation Disease/Phenotype
AD Alzheimer’s disease LM Lipid measurements
AF Atrial Fibrillation/Atrial Flutter LOAD Late-onset Alzheimer’s disease
ALS Amyotrophic Lateral Sclerosis LONG Longevity and age-related phenotypes
BA Brain aging MHA Minor histocompatibility antigenicity
BC Breast cancer MI Myocardial infarction
BD Bipolar disorder MS Multiple sclerosis
BL Blood lipids ND Nicotine dependence
BMG Bone mass and geometry NEU Neuroticism
BPAS Blood pressure and arterial stiffness OBE Obesity-related traits
CA Childhood asthma PA Polysubstance addiction
CAD Coronary Artery Disease PC Prostate cancer
CC Colorectal cancer PD Parkinson’s disease
CD Crohn’s disease PF Pulmonary function phenotypes
CDI Celiac disease PR Psoriasis
CS Coronary spasm PSP Progressive Supranuclear Palsy
CVD Cardiovascular Disease outcomes QT Cardiac repolarization (QT interval)
EO Early onset extreme obesity RA Rheumatoid Arthritis
GCA General cognitive ability RLS Restless Leg Syndrome
GD Gallstone disease SA Subclinical atherosclerosis
GLA Glaucoma SALS Sporadic Amyotrophic lateral Sclerosis
HAE Hepatic adverse events with thrombin inhibitor ximelagatran SCP Sleep and circadian phenotypes
HBF Adult fetal hemoglobin levels (HbF) by F cell levels SLCL Serum LDL cholesterol levels
HEI Height SLE Systemic Lupus Erythematosus
HEM Human episodic memory SP Schizophrenia
HIV1 HIV-1 disease progression SPBC Sporadic post-menopausal breast cancer
HT Haematological (blood) traits SPM Skin pigmentation
HYP Hypertension STR Stroke
IC Iris color T1D Type I Diabetes
IMAN Immunoglobulin A nephropathy T2D Type II Diabetes
IS Ischemic stroke TG Triglycerides
KFET Kidney function and endocrine traits
doi:10.1371/journal.pone.0027175.t001
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in Table S2. Using an LD threshold of r
2$0.5, the initial set of
15,388 unique SNPs was expanded to approximately 70,000
unique SNPs for the YRI population, and approximately 130,000
unique SNPs for the other populations. The high correlation
between the original and adjusted datasets indicated a linear
increase in the number of SNPs (Table 2 with graphs located in
Figure S2).
In addition to comparing the individual SNPs associated with
different diseases and phenotypes, we compared blocks of SNPs
clustered on the basis of LD. SNP blocks were created by
combining SNPs with an LD threshold of r
2$0.1. This produced
approximately 12,000 SNP blocks for each of the populations,
with approximately 20% of the blocks containing one SNP. The
SNPs clustered in each block were likely to be associated with
similar expression patterns and common function given the genetic
proximity of these variants, making it appropriate to analyze
disease/phenotype similarity at this level. In the earlier research by
Huang et al., SNPs were clustered based simply on genetic
distance [10], but this would have produced blocks containing
SNPs with very little LD between them, and therefore were
unlikely to have similar expression or function.
Relatedness increased across the analysis levels
The Jaccard index values were tallied for each analysis level and
a histogram of the values was assessed (Figure 1). The distribution
shifted toward a higher degree of relatedness and more non-zero
values as we progressed from one level to the next. A majority of
the non-zero Jaccard index values was observed for the pathway
level, with most of those values suggesting a relatively high level of
similarity. The opposite was true for the initial SNP level with a
small percentage of the non-zero indexes represented as low
Jaccard index values. Greater contrast between diseases and
phenotypes was observed at the SNP level as each disease or
phenotype contained association-specific SNPs. As the SNP level
was translated to block data, causal SNPs were grouped. This
trend of grouping continued as we progressed to the gene level,
and finally the pathway level. This grouping reduced the amount
of disease/phenotype-specific characteristics, but allowed for a
higher degree of relatedness as pathways contain multiple genes.
This indicated diseases/phenotypes with completely different gene
sets may share pathways if both sets of genes were present in the
common pathways.
Spearman correlations between levels for all populations
(Table 3) and between populations for all levels (Table 4) were
conducted to assess similarity between the datasets. The highest
correlation between the datasets for all populations was seen when
the SNP and block levels of data were compared. The least
correlation was observed between the pathway level and the other
three analysis levels. The correlations between populations for
each level were strong for all analysis levels. The pathway level
showed the highest similarity for all populations, with the greatest
correlation between the Asian populations. This trend of high
correlation between Asian populations was also seen for the SNP,
block, and gene levels. We hypothesized the correlation assessment
would indicate if the combined CHB+JPT population listed in
HapMap release #24 could be used instead of the individual
populations. As differences in the degree of correlation between
the populations changed for each level, and the list of SNPs
differed slightly for each population, all three populations were
considered for the disease/phenotype comparison steps.
Visualization of similarity indexes with DRNs
The Jaccard indexes did not indicate statistically strong
relationships at all levels. The maximum index values across all
populations for each level were 0.28, 0.54, 0.41, and 0.89 for the
SNP, block, gene, and pathway levels, respectively. The metric
suggested strong statistical similarity for data in the pathway level
only. Rather than directly interpreting Jaccard indexes as a
measure of similarity, the strength of relatedness was assessed
relatively for each level. For example, two diseases with a similarity
value of 0.28 for the SNP level would have more in common than
two diseases with a Jaccard index of zero.
The Jaccard index values were used to construct DRNs for each
level of analysis within each population (Figures 2 and 3). Each
disease and phenotype was assigned to a node, and edges were
drawn between each pair of nodes. Edge color and thickness (blue
to red and thin to thick, respectively) were adjusted to reflect
increasing index values. As thicker lines would indicate strong
relationships relative to the range of similarity index values for a
given level, diseases/phenotypes connected by such lines were the
focus of visual inspection. The SNP, block, and gene levels of
analysis consistently showed high relatedness between RA, T1D
and Multiple Sclerosis (MS) for all populations (Figure 2). We also
saw relatively consistent significance for hematological traits (HT)
and adult fetal hemoglobin level (HBF).
A strong association between serum low-density lipoprotein
cholesterol level (SLCL) and lipid measurements (LM) was seen
only at the SNP level for CEU, CHB, and CHB+JPT (Figure 2A,
B, D). This association was seen as less significant for the JPT and
YRI populations (Figure 2C and E) and for all populations in the
block (Figure 2F-J) and gene levels (Figure 2K-O). Other
associations displayed as thick blue lines indicated less significant









Figure 1. Distribution of Jaccard index values for all popula-
tions and levels. Histogram illustrating distribution of Jaccard Index
values for all populations at each level of analysis. Frequencies are
represented on a base ten logarithmic scale from zero (0) to 10,000.
doi:10.1371/journal.pone.0027175.g001
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for the gene level data. This suggested more relationships with
index values greater than zero, but not as significant as the
previously mentioned associations. It is possible that this indicates
some increase in clustering of casual SNPs shared across diseases.
For the pathway level, the maximum edge thickness was reduced
for ease of viewing as the number of relatively significant
associations at this level was high (Figure 3). The strong associations
seen at the pathway level did not directly match what was seen as
consistent across the SNP, block, and gene levels. For instance, the
strong MS-RA-T1D associations were missing. Instead, we saw
strong associations between SLCL, longevity and age-related
phenotypes (LONG), and early onset extreme obesity (EO) as one
group, and sporadic Amyotrophic Lateral Sclerosis (SALS),
immunoglobulin A nephropathy (IMAN), and celiac disease (CDI)
as another. The number of relatively significant relationships at this
level made it difficult to identify the strongest relationships. It was
observed that some of the less significant relationships seen at the
gene level (thick blue lines) were seen as more significant
relationships at the pathway level (red and orange lines). As
pathways were composed of many different gene products, it is
possible that uncommon lists of genes can all be present in a single
pathway. This interesting occurrence was seen for various disease/
phenotype pairs including AD-Parkinson’s Disease (PD), T2D-PD,
T2D-HIV1 and MS-HIV1. These diseases most likely share
pathways in which disease progression occurs even though the
affected genes are not identical. It is also important to note that a
loss of some diseases and phenotypes from the comparison list was
seenatthepathwaylevel(TableS1).Thereasonforthislosswasdue
to limitations of matching gene information between the HapMap,
Ensembl, and KEGG databases. This data limitation could also
have influenced absent associations, but did not appear to account
for the missing MS-RA-T1D associations. Pathway data for HBF
and SLCL were missing, however. Therefore, the HBF-HT and
SLCL-LM associations were absent at the pathway level.
Strongest disease associations identified via PCA
The DRNs constructed based on the Jaccard indexes were dense,
which made it difficult to verify significant relationships common
across populations and levels of analysis. Genetic relatedness that
translated to disease/phenotype association should be evident in
clinical literature. Given the amount of clinical information
available for the diseases and phenotypes included in this study, a
pair-by-pair search for clinical evidence would take an extensive
amount of time. Instead, the most significant relationships were
identified to assess clinical relevance. A principal component cluster
analysis method as proposed by Beckman et al. [18] was used to
extract significant relationships within the first three analysis levels.
The initial clustering was done across all levels of analysis and
the proportion of variance for each population was assessed
(Figure S3). PCA for all four comparison levels resulted in the first
three components explaining over 85% of the variance. This was
not surprising since only four principal components were assessed
given each level was considered a single variable. Additional
analysis was carried out based on coupled SNP and block levels,
SNP and gene levels, block and gene levels, and finally the SNP,
block and gene levels as a group. Only the SNP, block, and gene
analysis levels were assessed for most significant relatedness rather
than all four levels because missing cross referenced data resulted
in a lack of correlation between these three and the pathway data.
As shown in Table 5, the results were consistent across all but one
coupled clustering. Notably, the MS-RA-T1D association ap-
peared consistently for all populations across the first three levels,
which matched what was seen in the DRNs. Though not
Table 3. Spearman correlations between analysis levels for
each population.
CEU Block Gene Pathway
SNP 0.767 0.552 0.349
Block 0.523 0.302
Gene 0.481
CHB+JPT Block Gene Pathway
SNP 0.787 0.558 0.348
Block 0.527 0.299
Gene 0.481
CHB Block Gene Pathway
SNP 0.793 0.570 0.356
Block 0.539 0.292
Gene 0.495
YRI Block Gene Pathway
SNP 0.799 0.540 0.320
Block 0.510 0.283
Gene 0.487
JPT Block Gene Pathway




Table 4. Spearman correlations between populations for
each level of analysis.
SNP CHB JPT JPT+CHB YRI
CEU 0.873 0.857 0.874 0.836
CHB 0.937 0.970 0.829
JPT 0.955 0.805
CHB+JPT 0.835
Gene CHB JPT JPT+CHB YRI
CEU 0.922 0.872 0.916 0.924
CHB 0.907 0.962 0.892
JPT 0.937 0.834
CHB+JPT 0.886
Block CHB JPT JPT+CHB YRI
CEU 0.898 0.891 0.910 0.887
CHB 0.944 0.968 0.890
JPT 0.976 0.885
CHB+JPT 0.906
Pathway CHB JPT JPT+CHB YRI
CEU 0.963 0.965 0.978 0.969





PLoS ONE | www.plosone.org 5 November 2011 | Volume 6 | Issue 11 | e27175Figure 2. Human disease relatedness networks (DRNs) for 61 diseases and phenotpyes. DRNs across three levels of SNP data analysis for
five populations: CEU (A, F, K), CHB (B, G, L), JPT (C, H, M), CHB+JPT (D, I, N), and YRI (E, J, O). The three levels of analysis were SNP (A-E), blocks (F-J),
and genes (K-O). The placement of disease/phenotype abbreviations was consistent for all DRNs for ease of comparison. The width of the edge and
color correspond to the Jaccard indexes for each disease pair. Line width increases from small to large indexes. The color scale increases in the order
blue, green, yellow, orange, and red. The inserted table lists index percentile cutoff values for each line color designation. Line colors were designated
according to a gradient of the listed colors from minimum to maximum Jaccard index.
doi:10.1371/journal.pone.0027175.g002
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Triglycerides (TG), and EO-TG relationships matched what was
visually observed in the DRN assessment. The strongest
relationships seen for the SNP-block and SNP-gene analyses
matched. The RA-T1D association was listed as significant for all
levels, and proved the only strong relationship for 4 out of 5
populations for the block-gene clustering. The SNP-block and
SNP-gene analysis returned more significant relationships than the
block-gene group suggesting the block to gene progression was less
significant in the increase in degree of relatedness. The CHB+JPT
population showed significant association between EO and TG for
the SNP-block, SNP-gene, and SNP-block-gene cluster groups,
but this association was not observed in the individual JPT and
CHB populations. This is an association that is less pronounced in
the SNP and block DRNs for the three Asian populations
(Figure 2B, C, D, G, H, and I) and not visible at all for the gene
DRNs (Figure 2L, M, and N). Further, the BC-SPBC and HBF-
HT pairs predominate for the block-gene cluster of the YRI
population appeared to be masked at the SNP level as these
associations were not present for the other analysis sets.
Comparison to Huang et al. results
The RA-T1D association found here matched conclusions set
forth by Huang et al. [10], but we did not see strong associations
between either of these diseases and CD. In the original study,
associations were made given block proximity. It was noted that the
number of genes shared at zero distance between blocks was higher
for the RA-T1D pair than CD and either disease [10]. It is possible
that the increase in the number of SNPs assessed in the current study
masked any association seen between CD and RA or T1D. Missing
cross-reference data could be to blame for lack of relatedness as well.
It is also possible that the change in block level assessment revealed a
lack of genetic association between causal variants for the diseases. A
closer look at the Jaccard index values for the pathway level for all
populations revealed the CD-RA pair possessed moderate similarity
(0.36–0.5), while the CD-T1D pair possessed low similarity (0.04–
0.2). Little to no relatedness was calculated for the other three levels.
Comparatively, the RA-T1D pair showed high similarity relative to
the maximum index values for the SNP, block, and gene levels, and
low similarity for the pathway level.
No genetic links were seen between CAD, HYP, and T2D in the
current study, which agreed with the results of the previous study.
The Jaccard indexes for all populations showed little to no
relatedness between these diseases. Association was seen between
CAD and T2D minimally for the first three levels (,0.06) and
moderately at the pathway level (0.51–0.56). Our results suggest
limited genetic similarity canbe found between this triad of diseases.
Discussion
Here we describe a step-wise means of elucidating relatedness
between diseases and phenotypes. This study suggests that it is
possible to find genetic similarities that can be overlooked during
GWAS by progressively grouping data at less discriminating levels.
Such results suggest genetic similarities may exist between diseases
and phenotypes, and that these may serve as a guide for physicians
to monitor for less common or seemingly unrelated symptoms and
subsequent disease onset. A general search of the literature
supported some of the disease relationships found in this study.
The strong associations between MS, RA, and T1D have been
suggested in editorials and letters concerning clinical studies were
patients have exhibited two of these diseases [21–24]. The authors
suggested shared autoimmune responses and/or a systemic
inflammation response are responsible for the predisposition seen
Figure 3. Human DRNs from pathway-level analysis for 61 diseases and phenotypes. Analysis for five populations: CEU (A), CHB (B), JPT
(C), CHB+JPT (D), and YRI (E). The edge width and color correspond to the Jaccard indexes for each disease pair. Line width and color is scaled the
same as in Figure 2. The inserted table lists index cutoff values for each line color designation.
doi:10.1371/journal.pone.0027175.g003
GWAS-Based Disease/Phenotype Association
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24]. Relatedness between HT-HBF, SLCL-LM, and TG-LM were
not surprising given these phenotypes assumingly share traits and
mechanisms of genetic regulation. For example, haematological
traits are those that determine leukocyte, erythrocyte, and platelet
phenotypes [25], while fetal hemoglobin levels have been linked to
diagnosis of erythrocyte-associated diseases, such as sickle cell
anemia [26]. The connection here may be due to shared blood cell
gene regulation and erythrocyte phenotypes.
The high overall similarity among the three Asian populations
(CHB, JPT and CHB+JPT) coupled with the variation between CEU,
YRI, and the Asian populations may indicate that subtle genetic factors
influence the susceptibility of populations to some diseases. It is also
possible that environmental factors, such as geographical separation,
may have some influence on genetic variations that have arisen over
generations. Admittedly, the limitation of the current GWAS data and
limitations of LD may also result in discovery bias for this study.
Associations unique to either the CHB or JPT populations showed up
in the CHB+JPT population. Given that unique associations did show
up for the individual populations, use of a combined population would
not be ideal regardless of the high correlation between the datasets. Use
of a combined population would potentially mask population-specific
associations as something common to the combined group. It is
possible that the amount of data available for a specific disease or
phenotype was not consistent between the populations. It is also
possible that unique associations are a result of this discrepancy in data
points. This notion reinforces the need for individual population data
versus combined population data. The issue also conflicts with the idea
that population-specific associations could be seen in a comparison
study. To ensure population-specificity, the quantities of SNP data for
each disease would have to be incorporated into the similarity decision
process. As we know the quantity of SNPs was inconsistent between
populations for each disease and phenotype. Therefore, predictions
about population were excluded from our analysis.
A surprising observation was the lack of certain associations that
have been seen in the literature. One example is the association
between T2D, CVD, and OBE. These results do not indicate a
strong genetic link between the diseases despite the prevalence in
the literature of clinical links [27–30]. Our findings agree with the
Huang et al. [10] study in that no genetic links were seen between
CAD, HYP, and T2D. The clinical grouping of these diseases
could be a consequence of differences in gene regulation that result
in converged systemic responses. It is plausible that the clinical
manifestations of the diseases are common because disruption of
homeostasis in different pathways can manifest as similar
symptoms. It is also possible that the events triggered by one
disease result in the manifestation of another because the disrupted
pathway may have systemic implications as is presumed to be the
case with the MS, RA, and T1D associations. The difference here
would be the lack of similar genes affected in the disruption. In
Table 5. Most significant disease relationships for each population determined by PCA.
Population SNP and block SNP and gene Block and gene SNP, block and gene





















YRI MS-RA MS-RA BC-SPBC MS-RA
MS-T1D MS-T1D HBF-HT MS-T1D
RA-T1D RA-T1D MS-RA RA-T1D
MS-T1D
RA-T1D
Principal components were assessed for the first three levels in pairs, and all together to identify the most significant relationships.
doi:10.1371/journal.pone.0027175.t005
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rather a seemingly consequential relatedness, which we could not
appropriately address in this study. Such analysis would require a
more detailed look at the genes identified for each disease and the
clinical manifestations that result from mutations in those genes.
Though the pathway level data were not ideally matched to the
other three levels, some useful information can still be assessed
given commonality in pathways involved in pathogenesis between
diseases. Interesting associations between metabolic and neuro-
logical diseases were observed. For example, links between CAD
and MS, T2D and PD, and OBE and ischemic stroke (IS) were
seen in the pathway DRNs. Some of these associations showed up
as less pronounced for the SNP, block, and gene levels, which was
a trend observed with previously mentioned associations. The link
between these two disease categories warrants further study. The
systemic inflammation issue proposed to drive pathogenesis for the
MS-RA-T1D associations or the ‘‘different genes, same pathways’’
conclusion may also play a role in the proposed associations
between metabolic and neurological diseases.
It is possible that the amount of data within the moderate range of
relatedness is too large to isolate specific disease pairs. Therefore,
these associations could have been masked by the strongest
associations listed in Table 5. It is also possible that the reduction
in data during the progression from block to gene and gene to
pathway levels could have excluded some genes common to multiple
diseases. With the increased density of GWAS the anomalies
observed in this study might be better understood. Attempts have
been made to combine large SNP datasets into one database openly
available to researchers. Such an undertaking is time consuming and
difficult given the amount of data and discrepancies in naming
processes, but the practicality of such work is evident. A consolidated
source of SNP data would improve analysis given the gaps observed
in our data. Inclusion of more data might improve association
predictability as this could reintroduce points of relatedness that were
missing here and resulted in missing disease/phenotype associations.
Further, incorporating additional databasesand filteringoutcommon
associations might improve upon the results of a larger-scale study
and may shed light on less common but still significant disease
relatedness. Mathematical methods have recently been used to
identify perturbation differences between pathway-specific gene sets
for two synthetic tissue platforms [31]. Such techniques could be
adjusted and used with the addition of annotations for diseases linked
to gene sets in order to incorporate multiple databases while reducing
masking by redundant associations.
McCarthy et al. suggested assessing relatedness between diseases
is an issue of exploring mechanisms that influence susceptibility
and phenotype expression [8]. The techniques and data described
here suggested that large-scale disease and phenotype association
studies are possible and that such testing can provide insight into
mechanistic similarities. Broad implications of this study warrant
monitoring of patients by physicians for signs of diseases with
shared systemic effects is necessary. We also see the potential for
shared therapeutic targets for diseases with similar genetic
susceptibility and phenotype expression. Goh et al. suggested that
diseases could be connected if at least one gene was shared in
which a disease-associated mutation could be found [32]. We have
successfully expanded on this idea by introducing Jaccard
similarity as a means to weight the degree of association relative
to other diseases in the comparison. Taking a multi-disease
analysis approach is a useful means of assessing patterns across
human diseases [32] that may shed light on more effective means
of treating and improving upon human health.
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